Íò²©Ë®¾§¹¬

TU Jian^1a, WANG Yanxiang^1a, ZHOU Zhigang^1b , YANG Ping^1c, LlU Xiaowang², YU Ping²

( 1. a. College of Pharmacy ,b. The Second Affliated Hospital, c. College of Clinical Medicine, CuilinMedical University, Guilin 541199, China; 2. College of Pharmacy, Nanhua University,Hengyang 421001.China)

Abstract Objective To explore the elfect and mechanism of liver X receptor ( LXR) agonist TO901317on the migration ability of MCF-7 human breast cancer cells. Methods MCF-7 cells were cultured in vitro.At first . MCF-7 cells were treated with 'T0901317 with different coneentrations for 24 h. and then the cellswere transfected with LXRo siRNA or treated with PDTC, a nuclear factor kB ( NF-kB ) inhibitor. The changes of migration ability of MCF-7 cells were detected by seratch healing experiment, and theexpressions of L.XRa, NF-kB p65 and lkBo were detected by Western blot. Results With the inerease of'T0901317 concentration, the migration ability of MCF-7 cells was obviously inhibited, and the differencewas statistically significant ( P<0.05 ). At the same time, the expressions of LXRa and lkBa increasedgradually , while the expression of NF-kB p65 decreased significantly. LXRa siRNA can significantly delaythe above-mentioned elflects of 'T0901317, and PD'TC treatment can further enhanee the inhibitory elfect ofT0901317 on breast cancer cell migration, Conclusion T0901317 can activate LXRa , down-regulate NF-kB p65 , up-regulate the expression of lkBo , and inhibit the migration of breast cancer cells.Keywords:T0901317; liver X receptor a ;NF-kB; MCF-7 breast cancer cells; cell migration

£Ä£Ï£É:£±£°.£±£¹£²£¹£¶/£ê.£ã£î£ë£é.£±£°£°£¸£­£²£´£°£¹.£²£°£²£´£­£°£±£­£°£±£°

PDFdownload£ºclick to download